Travoprost

Travoprost

Clinical data
Pregnancy category	C US
Routes of administration	Topical (eye drops)
ATC code	S01EE04 (WHO)
Legal status
Legal status	Schedule VI US
Identifiers
IUPAC name propan-2-yl 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-but-1-enyl]-cyclopentyl]hept-5-enoate
CAS Number	157283-68-6
PubChem CID	656627
DrugBank	APRD01271
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C26H35F3O6
Molar mass	500.548 g/mol

WikiDoc Resources for Travoprost
Articles
Most recent articles on Travoprost Most cited articles on Travoprost Review articles on Travoprost Articles on Travoprost in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Travoprost Images of Travoprost Photos of Travoprost Podcasts & MP3s on Travoprost Videos on Travoprost
Evidence Based Medicine
Cochrane Collaboration on Travoprost Bandolier on Travoprost TRIP on Travoprost
Clinical Trials
Ongoing Trials on Travoprost at Clinical Trials.gov Trial results on Travoprost Clinical Trials on Travoprost at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Travoprost NICE Guidance on Travoprost NHS PRODIGY Guidance FDA on Travoprost CDC on Travoprost
Books
Books on Travoprost
News
Travoprost in the news Be alerted to news on Travoprost News trends on Travoprost
Commentary
Blogs on Travoprost
Definitions
Definitions of Travoprost
Patient Resources / Community
Patient resources on Travoprost Discussion groups on Travoprost Patient Handouts on Travoprost Directions to Hospitals Treating Travoprost Risk calculators and risk factors for Travoprost
Healthcare Provider Resources
Symptoms of Travoprost Causes & Risk Factors for Travoprost Diagnostic studies for Travoprost Treatment of Travoprost
Continuing Medical Education (CME)
CME Programs on Travoprost
International
Travoprost en Espanol Travoprost en Francais
Business
Travoprost in the Marketplace Patents on Travoprost
Experimental / Informatics
List of terms related to Travoprost

Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It is also known by the brand name of Travatan, manufactured by Alcon Inc. Travoprost is a synthetic prostaglandin F 2α analogue. Its chemical name is isopropyl (Z)-7- [(1 R ,2 R ,3 R ,5 S )-3,5-dihydroxy-2-[(1 E ,3 R )-3-hydroxy-4-[(α,α,α-trifluoro- m -tolyl)oxy]-1- butenyl]cyclopentyl]-5-heptenoate.

Possible side effects of this medication are:

• May cause blurred vision;
• May cause eyelid redness;
• May permanently darken eyelashes;
• May cause eye discomfort;
• May eventually cause permanent darkening of the iris to brown (heterochromia);
• May cause a temporary burning sensation during use.
• May cause thickening of the eyelashes.

References

• http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500293.html